ESMO-ESTRO consensus statements on the safety of combining radiotherapy with EGFR, ALK, or BRAF/MEK inhibitors - PubMed
3 hours ago
- #radiotherapy
- #targeted therapy
- #toxicity
- Combining radiotherapy (RT) with EGFR, ALK, or BRAF/MEK inhibitors may improve treatment outcomes but risks increased toxicity.
- High-quality toxicity data is scarce, leading to a lack of evidence-based guidelines.
- ESMO and ESTRO conducted systematic literature reviews and Delphi consensus rounds involving 19 international experts.
- 57 clinical scenarios were evaluated, covering different drug classes and irradiated areas.
- 2745 records were screened, with 110 reports included in the final literature reviews.
- Consensus was reached on all 57 scenario-specific safety statements.
- For most scenarios, combining RT with targeted agents may increase toxicity, requiring drug interruption, dosage reduction, or major RT adaptation.